International Journal of Medical and Pharmaceutical Research
2026, Volume-7, Issue 2 : 3855-3858
Research Article
Retrospective study of Latent Tuberculosis infection among contacts of tuberculosis patients
 ,
 ,
Received
March 27, 2026
Accepted
April 22, 2026
Published
April 30, 2026
Abstract

Background: Retrospective study of Latent Tuberculosis infection among contacts of tuberculosis patients.

Aims and Objective: To find out the burden of latent tuberculosis infection among contacts of tuberculosis patients.

Material and Method: This retrospective study was conducted by collecting four years data of contacts exposed to tuberculosis patient from Intermediate Reference Laboratory, Tertiary care hospital in Sikkim.Case report form of the patients for a period of four years from January 2022 till December 2025 was analysed. Latent tuberculosis infection was diagnosed by Interferon Gamma Release Assay using Quantiferon Tuberculosis Gold Plus test.

Results: Out of 724 contacts ,295 (40.74%) was found to be positive for latent tuberculosis infection. The sex ratio among positive contacts was (1:1.25)  .The age group was ranging from 4 years to 89 years of age.

Conclusion: The Latent tuberculosis infection was found to be about 40.74% among contacts of tuberculosis patients.This study can guide the physician for early diagnosis and treatment of latent tuberculosis infection to reduce the burden of tuberculosis in the society.

Keywords
INTRODUCTION

Latent tuberculosis infection (LTBI) is  defined by the World Health Organization(WHO) as a state of persistent immune response to stimulation by Mycobacterium tuberculosis (MTB) antigens without evidence of clinically manifested active tuberculosis (TB)(1). The US Centers for Disease Control and Prevention defines LTBI as a person who is infected with Mycobacterium tuberculosis but has no clinical signs or symptoms of active tuberculosis(2). It is estimated that 23% of the world's population is infected with MTB and at risk of developing active TB. Latent tuberculosis  infection  can progress to active TB disease in roughly 5% to 15% of infected individuals over their lifetimes(3) .While most people with latent infection never develop the disease, the risk of progression is highest within the first 2 years after initial infection. Patients with latent TB infection are asymptomatic. Active tuberculosis disease must be excluded before testing for latent TB infection.

 

This  hospital based retrospective  study was done to find out the burden of LTBI among contacts of Tuberculosis patients .Chauhan A et al  published a systemic review and metaanalysis  in the Indian Journal of Medical Research in the year 2023,they analyzed data from 77 studies (including 31 cohort studies) from 2013-2022, there was pooled LTBI prevalence ,irrespective of risk, estimated at 41% (95% CI: 29.5-52.6%) based on community-based cohort studies while the general population prevalence,excluding high-risk was estimated at 36% (95% CI: 28-45%). They depicted a high LTBI burden among groups such as diabetes mellitus, smokers, malnourished, and alcoholics(4).Also in a cross-sectional study done  in Rumtek monastery  in east Sikkim ,  the overall LTBI rate was 44.2% (5).

 

Contact investigation is an essential component of the WHO’s TB management algorithms to detect those with LTBI among high-risk groups, and to initiate tuberculosis preventive treatment (TPT). Individuals of all ages who are in contact with patients with active TB infection are at a significantly increased risk of developing a new TB infection. WHO advocates that trained staff should elicit the required information from the index TB patients and counsel patients and their family members on the importance of LTBI testing, TPT initiation and completion.

 

WHO recommends the tuberculin skin test (TST) or interferon-gamma release assays (IGRA) to detect LTBI. IGRA results in fewer false-positive results than with TST (8). IGRA  results are not affected by Bacille Calmettee Gue´rin (BCG)-vaccination and by the majority of environmental mycobacteria; moreover, only one patient-visit is required. However, since these assays are based on an immune response detection, they have a poor sensitivity in children and in immune-compromised subjects furthermore, they do not discriminate between active TB and LTBI and poorly correlate with the risk of developing active disease. Exclusion of active TB is to be done by sputum Catridge based nucleic acid amplification test (CBNAAT)  before  the diagnosis of latent TB infection is made . Identifying and treating patients with latent tuberculosis infections is critical for NTEP goals.

 

METHODOLOGY:

This present study was  done in Intermediate Reference Laboratory in a tertiary care hospital.The case report form data containing  age,sex,demographic details of the contact, past history , any treatment history  was collected for analysis  from IRL  laboratory register   from January 2022 till December 2025 for a period of 4 years  maintained in the laboratory. Statistical analysis:Data  analysis was done using excel .Categorical variables were presented as percentages .

Institutional Ethics Committee clearence was taken for the study.

 

RESULTS :

There was a total of 724 blood samples from  suspected contact during the period of four years from January 2022 till December 2025. Out of  724 only 295 (40.74%) blood sample was positive IGRA while out of remaining 429 (59.25%) there was 91 ( 12.56%) was indeterminate and 338 (46.68%) was negative . (Table 1). In the year 2022, out of 299 samples tested for LTBI, 126 (42.14%) were positive, 161 (53.84%)were negative and 12 (4.01%) were indeterminate.In the year  2023, out of 103 samples tested for LTBI, 34 (33.00%) were IGRA positive, 26 (25.24%) were IGRA negative and 43 (41.74%) were IGRA indeterminate.In the year  2024, out of 132samples tested for LTBI, 53 (40.15%) were IGRA positive, 69 (52.27%) were IGRA negative and 10 (7.57%) were IGRA indeterminate.while in the year 2025, out of 190 samples tested for LTBI, 82 (43.15%) were IGRA positive, 82 (43.15%) were IGRA negative and 26( 13.68%) were IGRA indeterminate.

 

The age group was ranging from 4 years upto 89 years among IGRA positive  during the entire four years period.The median age was 33years,29 years,29 years,39years among  the 126,34,53,82 IGRA positive in the year 2022,2023,2024 and 2025 respectively.(Table no 2)

 

The overall male to female sex ratio was (1:1.25) .In the year 2022, out of the 126 IGRA positives, 52/126 (41.26 %) were males, 74/126 (58.73%) were females. In the year 2023, out of the 34 IGRA positives, 16/ 34 ( 47.05% ) were males, 18/ 34( 52.94%) were females. In the year 2024,out of the 53 IGRA positives,16/53(30.18%) were males, 37/53 (69.81%) were females.In the year  2025,out of the 82IGRA positives,47/82 ( 57.31% ) were males, 35/82  ( 42.68% ) were females.(Table no.3)

 

Table 1.Total  blood samples tested for IGRA from January 2022 till December 2025

 

YEAR

 

IGRA Positives

 

IGRA Negatives

 

IGRA Indeterminates

2022

126/299

(42.14%)

161/299

(53.84%)

12/299

(4.01%)

2023

34/103

(33.00%)

   26/103

  (25.24%)

43/103

 (41.74%)

 

2024

53/132

(40.15 %)

69/132

(52.27%)

10/132

( 7.57% )

 

 

2025

 

82/190

(43.15%)

 

 

82/190

(43.15%)

 

 

26/190

(13.68%)

 

Total

295/724

(  40.74%)

338/724

( 46.68% )

91/724

( 12.56% )

Table no 2. Age distribution among IGRA Positives :

Age groupsin years

2022 Year

2023 Year

2024Year

2025Year

Total

<10

23

3

1

1

28

11-20

25

8

6

5

44

21-30

44

11

20

15

90

31-40

21

7

11

28

67

41-50

9

3

9

9

30

51-60

3

2

4

17

26

>60

1

 

2

7

10

 

Table no 3. Sex Distribution

Sex

2022

2023

2024

2025

male

52/126

(41.26%)

16/ 34

(47.05 % )

16/53

(30.18%)

47/82 

(57.31%)

female

74/126

(58.73% )

18/34

(52.94% )

37/53

(60.81%)

35/82 

(42.68% )

Total IGRA positives

126

 

34

 

53

 

82

 

 

DISCUSSION:

The national tuberculosis  prevalence survey done in the year 2019 till 2021 estimates that the prevalence of LTBI in India  was found to be 33%(6). Studies from Vietnam, Indonesia and Philippines reported LTBI rates from 30% to 50% in high risk groups(7). Similarly a meta analysis done by Chauhan A et al where 41% prevalence was seen  in a community based cohort study in population with high risk groups(4). However in our retrospective hospital based  study,  the LTBI positivity was  around 40.74%.  

 

The proportion of infection rises with age especially in Africa and south east region, where there was more LTBI  in the younger age groups while in Europe and American regions older age group was affected(8).An increasing trend of TBI was observed with increasing age in India(4).However our  study also shows Latent bacterial tuberculosis infection mostly among  adult age group.

 

For detecting LTBI infection ,there are three  standard  tests namely Tuberculin skin test (TST),  Interferon-gamma (IFN-γ) release assays (IGRA) and Cy-TB test. In the present study IGRA was used for diagnosing Latent Tuberculosis infection.

Majority of the LTBI  individuals (around 90 − 95%) remain latent throughout their life and rest develop active cases of TB. However, deficiency in immunity level can lead an individual  to develop active TB(9).LTBI testing and treatment  in high-risk groups, such as people living with HIV, and close contacts of TB cases will reduce the burden and subsequent re activation to TB disease. Risk of contracting TBI is significantly greater among household contacts compared to general population (10,11,12).

 

CONCLUSION:

The present study showed the positivity rate of Latent Tuberculosis  Infection was  40.74% among contacts of tuberculosis patients by IGRA. Hence our study can guide the physician the need for prompt diagnosis and treatment of LTBI  thereby  reducing the burden of LTBI in the contacts and  the possibility of re activation to TB disease .

 

REFERENCES:

  1. World Health Organization. Latent TB Infection (2018): Updated and Consolidated Guidelines for Programmatic Management. Geneva, Switzerland: World Health Organization:WHO/CDS/TB/2018.4
  2. CDC (2025), Clinical overview of Latent Tuberculosis Infection .Apr;17
  3. Comstock GW, Livesay VT, Woolpert SF 1974. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. Feb;99(2):131-8. 
  4. Chauhan A, Parmar M, Dash GC, Solanki H et al 2023 . The prevalence of tuberculosis infection in India: A systematic review and meta-analysis. Indian J Med Res.Feb-Mar;157(2&3):135-151.
  5. Siddiqui MK, Khan S, Bhutia R,Nair V,Rai A, Gurung N, et al. (2025) Prevalence and factors associated with tuberculosis infection (TBI) among residents of a monastery situated in a high-TB burden area: A cross-sectional study, Sikkim, India.PLoS One 20(10): 2025
  6. National TB Prevalence survey in India 2019-2021 Central TB Division .https://tbcindia.mohfw.gov.in/2023/06/06.
  7. WHO Global Tuberculosis Report (2023) 7 November 2023;75.
  8. Houben RMGJ, Dodd PJ (2016) The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med 25;13(10):2016.
  9. Dhiraj Kumar Das, T.K. Kar (2020),Dynamical analysis of an age-structured tuberculosis mathematical model with LTBI detectivity,Journal of Mathematical Analysis and Applications,Volume 492, Issue 1,2020,124407,ISSN 0022-247X
  10. Ntshiqa T, Nagudi J, Hamada Y, Copas A, Sabi I, et al(2025). Risk Factors Associated With Tuberculosis Infection Among Household Contacts of Patients With Microbiologically Confirmed Pulmonary Tuberculosis in 3 High Tuberculosis Burden Countries. J Infect Dis. 2025;232(3):448–58.
  11. Lienhardt C, Fielding K, Sillah JS, Bah B, Gustafson P, Warndorff D, et al.(2005) Investigation of the risk factors for tuberculosis: a case-control study in three countries in West Africa. Int J Epidemiol. 2005;34(4):914–23.
  12. Morrison J, Pai M, Hopewell PC (2008). Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in lowincome and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8(6):359–68.

 

Recommended Articles
Research Article Open Access
A Cross-Sectional, Questionnaire-Based Assessment of Knowledge, Attitude, and Practice Concerning Antibiotic Use among Medical Undergraduates
2026, Volume-7, Issue 2 : 3859-3866
Case Series Open Access
Rare Presentations of Cutaneous Rhinosporidiosis-A Case Series from A Tertiary Health Care Centre of Western Odisha
2026, Volume-7, Issue 2 : 3867-3872
Research Article Open Access
Comparative Study between Open CBD Exploration and Laparoscopic CBD Exploration in Choledocholithiasis Patients in a Tertiary Care Centre
2026, Volume-7, Issue 2 : 3847-3854
Case Series Open Access
Cutaneous Manifestations Associated with Autoimmune Thyroiditis in Males: A Case Series of Five Uncommon Presentations
2026, Volume-7, Issue 2 : 3826-3833
International Journal of Medical and Pharmaceutical Research journal thumbnail
Volume-7, Issue 2
Citations
5 Views
8 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
Creative Commons Attribution License Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
facebook twitter linkedin mendeley research-gate
© Copyright | International Journal of Medical and Pharmaceutical Research | All Rights Reserved